Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers (nm). Exosomes are formed by the invagination of the cell membrane. This invagination and subsequent budding result in the formation of early endosomes. These early endosomes then mature into late endosomes, which are also called multivesicular bodies (MVBs). Finally, these MVBs migrate and fuse with the plasma membrane to release exosomes outside the cell. [Read more…]
104 Current & Future Uses of Umbilical Cord Stem Cells (Today in 2025)
Umbilical cord stem cells are present within the cord that connects a newborn to its mother and uses of these birth cells include treating cancers, diseases, injuries, and more. Umbilical cord blood contains hematopoietic stem cells (HSCs), which are multipotent stem cells that can give rise to other blood and immune system cells.
Stem cells can also be collected from a newborn’s:
- Umbilical cord tissue (Wharton’s jelly)
- Placenta
- Amnion
Most commonly, hematopoietic stem cells (HSCs) from cord blood are used to treat blood cancers, such as leukemia. When compared to hematopoietic stem cells from genetically matched bone marrow donor, cord blood HSCs may provide some medical advantages, including fewer immune system complications, such as graft-versus-host disease (GvHD).
In recent years, regenerative medicine has continued to increase the list of medical uses for stem cells from umbilical cord. Find out more about current and future uses of umbilical cord stem cells below.
In this article:
Cord Blood Market Intelligence: A Region-By-Region Analysis
The practice of cord blood banking, where stem cells from a newborn’s umbilical cord are preserved for potential future medical use, has gained significant traction worldwide. However, adoption rates, regulatory frameworks, and public awareness vary significantly across geographic regions. In some areas, robust public and private banking systems drive widespread participation, while in others, the practice remains nascent, shaped by cultural attitudes, healthcare infrastructure, and policy.
In addition to being complex industry, it is also a recent industry. It was not until 1974 that it was first proposed that progenitor cells were present in human cord blood and 1983 that umbilical cord blood was proposed as an alternative source of stem cells for transplant. In 1988, the first successful cord blood transplant occurred, but it was not until 1995 that the first private cord blood bank began operations.
Since 1988, stem cells from umbilical blood have been used in more than 40,000 transplants worldwide.
Stem Cell Therapy as Hemophilia Treatment
Traditionally, hemophilia treatment has leveraged injections of a clotting factor or plasma. Learn more about how stem cells may hold promise for treating hemophilia using a cellular approach.
In this article:
Cellistic® Announces Successful Certification of its GMP Facility Dedicated to iPSC-Based Off-the-shelf Cell Therapy Manufacturing Solutions
MONT-SAINT-GUIBERT, Belgium — Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its first-of-its kind facility dedicated to manufacturing therapies based on induced pluripotent stem cells (iPSCs). This achievement signifies Cellistic’s quality and regulatory readiness, which is now certified by the Belgian Federal Agency for Medicines and Health Products (FAMHP), operating under European Medicines Agency (EMA) guidelines. [Read more…]
- « Previous Page
- 1
- …
- 77
- 78
- 79
- 80
- 81
- …
- 334
- Next Page »